Target intelligence / Profile preview

Receptor-type tyrosine-protein phosphatase U (PTPRU)

Target
PTPRU
Molecular classification
Enzyme (Protein tyrosine phosphatase family), Receptor (Receptor-type protein tyrosine phosphatase), Pseudophosphatase (non-catalytic domains; scaffold function)
01

Overview

Receptor-type tyrosine-protein phosphatase U (PTPRU) is a cell surface receptor protein encoded by the human PTPRU gene. It is part of the R2B subfamily of receptor-type protein tyrosine phosphatases and features extracellular domains enabling cell-cell interactions, as well as two intracellular phosphatase domains. Unlike typical receptor-type PTPs, structural and biochemical studies show both PTPRU domains lack phosphatase activity and instead function as pseudophosphatase scaffolds. PTPRU regulates cellular processes—not by dephosphorylation but by protecting shared substrates from dephosphorylation, fine-tuning cell junction formation, growth, differentiation, and signaling, and is involved in pathological contexts including tumor progression

Other names
PTPRUReceptor-type protein-tyrosine phosphatase UPTP piPCP-2hPTP-JPTPROPTP psiPancreatic carcinoma phosphatase 2Protein-tyrosine phosphatase JProtein-tyrosine phosphatase piReceptor-type protein-tyrosine phosphatase omicronR-PTP-UPCP2PTP-JFMI
02

Mechanism of action

Scaffold or substrate competitor, not enzymatic dephosphorylation Functions as a negative regulator by sequestering protein substrates such as β-catenin from active phosphatases, thereby protecting phosphotyrosine states relevant to cell adhesion and signal transduction

03

Biological functions

Signal transductionCell adhesionRegulation of cell growth and differentiationCell cycle controlMaintenance of epithelial integrityCell proliferation and migration
04

Disease associations

Cancer (glioma, other tumor progression)Potential involvement in cardiovascular and other diseases linked to phosphorylation deregulation
05

Safety considerations

Therapeutic targeting of pseudophosphatases like PTPRU presents challenges due to lack of catalytic activity and diverse scaffolding interactions; potential off-target effects in signaling networks
06

Interacting drugs

No approved drugs directly target PTPRU; modulating PTP family function is under investigation for future therapeutic development
07

Biomarkers

PTPRU expression correlates with malignancy grade in glioma and other tumors; altered splicing or nuclear localization may provide prognostic value

Beyond the preview

Go deeper on Receptor-type tyrosine-protein phosphatase U (PTPRU).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Receptor-type tyrosine-protein phosphatase U (PTPRU).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call